This press release contains no new financial data, guidance, or material corporate developments. It is a routine brand-building communication. No trading action is warranted based on this filing.
Price Chart
Executive Summary
Medifast (MED) issued a press release highlighting OPTAVIA's clinical research portfolio, including 18 randomized controlled trials and a study showing 98% lean mass preservation. The release is promotional and lacks new financial data or material corporate events, making it a routine brand-building communication with no immediate stock-moving impact.
Key Facts
- OPTAVIA's research portfolio includes 18 randomized controlled trials and 100+ peer-reviewed presentations/publications.
- A 16-week RCT found OPTAVIA Optimal Weight 5 & 1 Plan preserved 98% of lean mass.
- Clients with coaching lost up to 10x more weight and 17x more fat than those without coaching.
- No new financial results, guidance, or material corporate events were disclosed.
Financial Impact
No financial impact; press release is a marketing summary of existing clinical data.
Risk Factors
- Press release may be viewed as a defensive response to competition from GLP-1 drugs, but no concrete strategy changes were announced.
- No new financial data means no catalyst for near-term stock movement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296057 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | — | awaiting T+5 | — | — |
Oct 15, 2026 11d ago | Press Release | $12.06 $12.17 | ▲ +0.91% | ▲ +1.93% | $11.87 (−1.58%) |
Oct 6, 2026 20d ago | Press Release | $11.51 $11.67 | ▲ +1.39% | ▲ +1.53% | $11.87 (+3.13%) |
Oct 1, 2026 25d ago | Press Release | $11.43 $11.43 | · 0.00% | ▼ −1.30% | $11.87 (+3.85%) |
Aug 28, 2026 8w ago | Insider Buy | $12.18 $12.63 | ▲ +3.69% | ▲ +3.59% | $11.87 (−2.55%) |
Aug 26, 2026 8w ago | Insider Buy | $12.22 $12.67 | ▲ +3.68% | ▲ +3.80% | $11.87 (−2.86%) |
Aug 21, 2026 9w ago | Insider Buy | $11.95 $12.18 | ▲ +1.92% | ▲ +1.45% | $11.87 (−0.67%) |
Jul 17, 2026 14w ago | 8-K | $10.26 $9.45 | ▼ −7.89% | ▼ −7.21% | $11.87 (+15.69%) |
Jun 1, 2026 21w ago | 8-K | $12.70 $12.10 | ▼ −4.72% | ▼ −1.97% | $11.87 (−6.54%) |
May 26, 2026 21w ago | 8-K | $12.72 $12.36 | ▼ −2.83% | ▼ −4.04% | $11.87 (−6.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers